De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation

Cancer Research

Volumn 69, Issue 22, 2009, Pages 8662-8669

  Liu, Ji Wei ^a   Sun, Ping ^b   Yan, Qiu ^a   Paller, Amy S ^b   Gerami, Pedram ^b   Ho, Nancy ^b   Vashi, Neelam ^b   Le Poole, I Caroline ^c   Wang, Xiao Qi ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM3; GELATINASE A; UROKINASE RECEPTOR;

ARTICLE; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; G(M3) GANGLIOSIDE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; NEOPLASM INVASIVENESS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 72249088570     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1099     Document Type: Article

References (50)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
2. Sun P, Wang XQ, Lopatka K, Bangash S, Paller AS. Ganglioside loss promotes survival primarily by activating integrin-linked kinase/Akt without phosphoinositide 3-OH kinase signaling. J Invest Dermatol 2002;119:107-117 (Pubitemid 35304398)
3. Wang XQ, Rahman Z, Sun P, et al. Ganglioside modulates ligand binding to the epidermal growth factor receptor. J Invest Dermatol 2001;116:69-76. (Pubitemid 32108756)
4. Wang XQ, Sun P, Go L, Koti V, Fliman M, Paller AS. Ganglioside GM3 promotes carcinoma cell proliferation via urokinase plasminogen activator-induced extracellular signal-regulated kinase-independent p70S6 kinase signaling. J Invest Dermatol 2006;126:2687-2696 (Pubitemid 44764053)
5. Wang XQ, Sun P, Paller AS. Inhibition of integrinlinked kinase/protein kinase B/Akt signaling: mechanism for ganglioside-induced apoptosis. J Biochem (Tokyo) 2001;276:44504-44511 (Pubitemid 37391224)
6. Wang XQ, Sun P, Paller AS. Ganglioside induces caveolin- 1 redistribution and interaction with the epidermal growth factor receptor. J Biochem (Tokyo) 2002;277: 47028-47034 (Pubitemid 36159210)
7. Wang XQ, Sun P, Paller AS. Ganglioside modulation regulates epithelial cell adhesion and spreading via ganglioside- specific effects on signaling. J Biochem (Tokyo) 2002;277:40410-40419 (Pubitemid 35215616)
8. Wang XQ, Sun P, Paller AS. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J Biochem (Tokyo) 2003;278:48770-48778 (Pubitemid 41079519)
9. Wang XQ, Sun P, Paller AS. Ganglioside GM3 inhibits matrix metalloproteinase-9 activation and disrupts its association with integrin. J Biochem (Tokyo) 2003;278: 25591-25599 (Pubitemid 36835312)
10. Wang XQ, Sun P, Paller AS. Gangliosides inhibit urokinase-type plasminogen activator (uPA)-dependent squamous carcinoma cell migration by preventing uPA receptor/αβ integrin/epidermal growth factor receptor interactions. J Invest Dermatol 2005;124:839-848 (Pubitemid 40489513)
11. Wang XQ, Yan Q, Sun P, et al. Suppression of epidermal growth factor receptor signaling by protein kinase C-α activation requires CD82, caveolin-1, and ganglioside. Cancer Res 2007;67:9986-9995 (Pubitemid 47621249)
12. Birkle S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003;85:455-463 (Pubitemid 36626016)
13. Hakomori SI. Bifunctional role of glycosphingolipids. Modulators for transmembrane signaling and mediators for cellular interactions. J Biochem (Tokyo) 1990; 265:18713-18716 (Pubitemid 20378512)
14. Hakomori SI. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002;99:10231-10233
15. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 1987;78: 45-54.
16. Saha S, Mohanty KC. Enhancement of metastatic potential of mouse B16-melanoma cells to lung after treatment with gangliosides of B-16-melanoma cells of higher metastatic potential to lung. Indian J Exp Biol 2003;41:1253-1258 (Pubitemid 37379307)
17. Saha S, Mohanty KC. Correlation of gangliosides GM2 and GM3 with metastatic potential to lungs of mouse B16 melanoma. J Exp Clin Cancer Res 2003;22:125-134 (Pubitemid 36396667)
18. Tardif M, Coulombe J, Soulieres D, Rousseau AP, Pelletier G. Gangliosides in human uveal melanoma metastatic process. Int J Cancer 1996;68:97-101. (Pubitemid 26354585)
19. Guthmann MD, Bitton RJ, Carnero AJ, et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 2004;27:442-451
20. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines 2003;2:817-823 (Pubitemid 37541567)
21. Guthmann MD, Castro MA, Cinat G, et al. Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an antiidiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006;29:215-223 (Pubitemid 43756097)
22. Wang Q, Zhang J, Guo Z. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibodymediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem 2007;15:7561-7567 (Pubitemid 47575927)
23. Bitton RJ, Guthmann MD, Gabri MR, et al. Cancer vaccines: an update with special focus on ganglioside antigens. Oncol Rep 2002;9:267-276
24. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40. (Pubitemid 30105328)
25. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-943 (Pubitemid 35477371)
26. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop 2003;415: S46-58.
27. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22:205-222 (Pubitemid 36561058)
28. Ragno P. The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol Life Sci 2006; 63:1028-1037 (Pubitemid 43800773)
29. Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997;137:767-777 (Pubitemid 27200676)
30. D'Alessio S, Margheri F, Pucci M, et al. Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer 2004;110: 125-133 (Pubitemid 38507212)
31. Almholt K, Lund LR, Rygaard J, et al. Reduced metastasis of transgenic mammary cancer in urokinasedeficient mice. Int J Cancer 2005;113:525-532 (Pubitemid 40038727)
32. Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T. Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons α and γ in human melanoma. Int J Cancer 1994;58:582-586
33. Wang XQ, Sun P, O'Gorman M, Tai T, Paller AS. Epidermal growth factor receptor glycosylation is required for ganglioside GM3 binding and GM3-mediated suppression of activation. Glycobiology 2001;11:515-522 (Pubitemid 32677828)
34. Krengel U, Olsson LL, Martinez C, et al. Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. J Biol Chem 2004;279:5597-5603 (Pubitemid 38220586)
35. Hanai N, Dohi T, Nores GA, Hakomori S. A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth. J Biol Chem 1988;263:6296-6301 (Pubitemid 18121661)
36. Kargiotis O, Chetty C, Gogineni V, et al. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol 2008;33:937-947
37. Park CM, Park MJ, Kwak HJ, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006; 66:8511-8519
38. van der Pluijm G, Sijmons B, Vloedgraven H, et al. Urokinase-receptor/ integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol 2001;159:971-982 (Pubitemid 32847188)
39. Postovit LM, Dutt P, Dourdin N, et al. Calpain is required for MMP-2 and u-PA expression in SV40 large T-antigen-immortalized cells. Biochem Biophys Res Commun 2002;297:294-301. (Pubitemid 35216169)
40. Wang XQ, Sun P, Al-Qamari A, Tai T, Kawashima I, Paller AS. Carbohydrate-carbohydrate binding of ganglioside to integrin α(5) modulates α(5)β(1) function. J Biol Chem 2001;276:8436-8444
41. McDaniel SM, O'Neill C, Metz RP, et al. Whole-food sources of vitamin A more effectively inhibit female rat sexual maturation, mammary gland development, and mammary carcinogenesis than retinyl palmitate. J Nutr 2007;137:1415-1422 (Pubitemid 46855479)
42. Lloyd KO, Furukawa K. Biosynthesis and functions of gangliosides: recent advances. Glycoconj J 1998;15: 627-636 (Pubitemid 28380325)
43. Chammas R, Sonnenburg JL, Watson NE, et al. De-Nacetyl- gangliosides in humans: unusual subcellular distribution of a novel tumor antigen. Cancer Res 1999;59: 1337-1346 (Pubitemid 29136267)
44. Carr A, Mullet A, Mazorra Z, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000;19:241-247 (Pubitemid 30622625)
45. Gabri MR, Mazorra Z, Ripoll GV, et al. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model. Clin Cancer Res 2006;12:7092-7098 (Pubitemid 44974509)
46. Irie RF, Ollila DW, O'Day S, Morton DL. Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother 2004;53: 110-117 (Pubitemid 38161217)
47. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008;8:315-323
48. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54: 3066-3071 (Pubitemid 24187797)
49. Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003;63:4757-4762
50. Sun P, Wang XQ, Go L, Paller AS. Ganglioside GM3 exerts reciprocal effects on MMP-9 and MMP-2 expression in the presence of uPA. J Invest Dermatol 2004;122: A29, 171.